Alumis
Pre-Approval PRO BETASlowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 4/29/2025
Pipeline by Phase
Therapeutic Focus
Clinical Trials (13)
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Started: 1/8/2025
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Started: 8/20/2024
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Started: 7/25/2024
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Started: 6/26/2023
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
Started: 1/17/2023
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
Started: 9/27/2022
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
Started: 6/14/2023
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Started: 4/29/2025
An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005
Started: 4/22/2024
An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001
Started: 6/21/2024
An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function
Started: 4/23/2025
Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants
Started: 5/12/2022
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
Started: 3/17/2022